Long Term Evaluation of Human Acellular Dermal Matrix Allograft For Coverage of the Wound After Extensive Deep Burn (ADM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01562119 |
Recruitment Status : Unknown
Verified April 2013 by Xiaolin Wang,Principal Investigator, Tang-Du Hospital.
Recruitment status was: Active, not recruiting
First Posted : March 23, 2012
Last Update Posted : April 19, 2013
|
Sponsor:
Tang-Du Hospital
Information provided by (Responsible Party):
Xiaolin Wang,Principal Investigator, Tang-Du Hospital
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date | March 21, 2012 | |||
First Posted Date | March 23, 2012 | |||
Last Update Posted Date | April 19, 2013 | |||
Study Start Date | January 2011 | |||
Estimated Primary Completion Date | May 2013 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures |
Function of the region covered by human acellular dermal matrix allograft [ Time Frame: March, 2012 to May, 2013 ] | |||
Original Primary Outcome Measures | Not Provided | |||
Change History | ||||
Current Secondary Outcome Measures |
Physical characteristics of the transplanted human acellular dermal matrix allograft [ Time Frame: March, 2012 to May, 2013 ] | |||
Original Secondary Outcome Measures | Not Provided | |||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title | Long Term Evaluation of Human Acellular Dermal Matrix Allograft For Coverage of the Wound After Extensive Deep Burn | |||
Official Title | Long Term Evaluation of Human Acellular Dermal Matrix Allograft For Coverage of the Wound After Extensive Deep Burn | |||
Brief Summary | The present study was to retrospectively evaluate the long-term outcomes of the cograft acellular dermal matrix (ADM) with autologous thin split-thickness skin for coverage of functional regional wounds in burned patients. | |||
Detailed Description | The potential of acellular dermal matrix (ADM) had been proved to improve cosmetic and functional outcomes, nevertheless, there had been few reports about the long term results of the morphological, histological and functional changes after placement. The present study was to retrospectively evaluate the long-term outcomes of the cograft acellular dermal matrix (ADM) with autologous thin split-thickness skin for coverage of functional regional wounds in burned patients. | |||
Study Type | Observational | |||
Study Design | Observational Model: Case-Control Time Perspective: Retrospective |
|||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Retention: Samples With DNA Description: The skin with ADM inplant and the nomal skin as control group
|
|||
Sampling Method | Non-Probability Sample | |||
Study Population | Thirty burn patients, treated by composite graft of ADM with autologous split-thickness skin from January 2007 to December 2009, were enrolled in this study. | |||
Condition |
|
|||
Intervention | Not Provided | |||
Study Groups/Cohorts | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status | Unknown status | |||
Actual Enrollment |
30 | |||
Original Actual Enrollment | Same as current | |||
Estimated Study Completion Date | May 2013 | |||
Estimated Primary Completion Date | May 2013 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria: |
|||
Sex/Gender |
|
|||
Ages | 3 Years to 52 Years (Child, Adult) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | China | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT01562119 | |||
Other Study ID Numbers | TDLL-2012109 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Xiaolin Wang,Principal Investigator, Tang-Du Hospital | |||
Study Sponsor | Tang-Du Hospital | |||
Collaborators | Not Provided | |||
Investigators |
|
|||
PRS Account | Tang-Du Hospital | |||
Verification Date | April 2013 |